Novartis news

Afinitor® recommended for use in the European Union for patients with advanced kidney cancer

Data on more than 15 Novartis Oncology compounds at ASCO highlight progress toward targeted therapies for diverse tumor types

Novartis increases its offer price on Novartis India Ltd.

Novartis to enter Japan vaccines market through agreement for Haemophilus Influenzae Type B (Hib) vaccine

Phase III data show Novartis investigational bronchodilator QAB149 significantly improves lung function over current treatments in COPD[1],[2]

Sandoz to acquire EBEWE Pharma specialty generics business, improving access for patients worldwide to injectable cancer drugs

Novartis announces restructuring of global collaboration with Schering-Plough to develop fixed-dose combination respiratory therapies

Novartis receives approval from FDA to market Prevacid® 24HR as first and only OTC proton pump inhibitor in original prescription formulation

Scientists who developed Novartis Coartem® and Glivec® receive 2009 ''European Inventor of the Year'' awards

Novartis names Jonathan Symonds deputy CFO and CFO designate

Syndicate content